302 patents
Page 7 of 16
Utility
Osimertinib for Use In the Treatment of Non-small Cell Lung Cancer
9 Jun 22
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.
Anthony Francis Patrick NASH
Filed: 27 Mar 20
Utility
Pyridine and pyrimidine derivatives
7 Jun 22
Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases.
Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
Filed: 17 Jul 20
Utility
Estrogen Receptor Degrading Protacs
2 Jun 22
Bin YANG, Thomas George Christopher HAYHOW, Charlene FALLAN, James Stewart SCOTT, Coura Rosalie DIENE, Bernard Christophe BARLAAM, Johannes Wilhelmus Maria NISSINK
Filed: 27 Mar 20
Utility
Mpo Inhibitors for Use In Medicine
26 May 22
The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
Andrew WHITTAKER, Hitesh Jayantilal SANGANEE
Filed: 2 Dec 21
Utility
Type I Interferon-mediated Disorders
26 May 22
The invention provides methods of identifying, diagnosing, treating, and monitoring or prognosing progression of type I IFN-mediated disease or disorder in subjects.
Kerry CASEY, Dominic SINIBALDI, Michael SMITH, Miguel SANJUAN
Filed: 14 Feb 20
Utility
Compositions and Methods for Improved Gene Editing
26 May 22
The present disclosure provides methods of introducing site-specific mutations in a target cell and methods of determining efficacy of enzymes capable of introducing site-specific mutations.
Marcello MARESCA, Songyuan LI
Filed: 9 Apr 20
Utility
Chemical compounds
10 May 22
Jeffrey Wallace Johannes, Sudhir Mahadeo Hande, Sebastien Louis Degorce, Martin John Packer
Filed: 17 Jul 20
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES for Treating Bronchiectasis
5 May 22
Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Reinilde HEYRMAN, Eugene SULLIVAN, Carlos FERNANDEZ
Filed: 14 Jan 22
Utility
Heteroaryl Compounds That Inhibit G12C Mutant Ras Proteins
28 Apr 22
Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
Filed: 5 Oct 21
Utility
Composition for inhalation
26 Apr 22
The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases.
Nayna Govind, Maria Marlow
Filed: 27 Mar 20
Utility
Method of Treating Fibrosis
21 Apr 22
The present disclosure concerns certain Src kinase inhibitors, or pharmaceutically-acceptable salts thereof, and their use in the treatment of fibrosis and fibrotic conditions, such as idiopathic pulmonary fibrosis, in a warm-blooded animal such as a human.
Leslie COUSENS, Chad NIVENS, Katherine Jane ESCOTT, Susan MONKLEY, Antje PRASSE
Filed: 26 Feb 20
Utility
Automated Detection of Safety Signals for Pharmacovigilance
31 Mar 22
An embodiment may involve obtaining a set of pre-defined features and a new document; extracting a subset of the pre-defined features from within new document; applying a natural language model to the new document, wherein the natural language model was pre-trained using scientific or medical literature and fine-tuned using a corpus of documents; applying a feature-based model to the subset of the pre-defined features extracted from the new document, wherein the feature-based model was trained with the pre-defined features and the respective labels of the documents; and applying an aggregation model to the classifications of the new document produced by the natural language model and the feature-based model, wherein the aggregation model was trained with prior classifications produced by the natural language model and the feature-based model so that the aggregation model produces a further classification of the new document representing its relevance to pharmacovigilance.
Alexandre Kiazand, Robert Hernandez, Antoni Wisniewski, Douglas Domalik, Tony Gill
Filed: 22 Jul 21
Utility
Pharmaceutical Composition
24 Mar 22
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
Filed: 6 May 21
Utility
Method of Treating Fatty Liver Disease
24 Mar 22
The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject.
Daniel LINDEN, Richard LEE, Stefano ROMEO, Huynh-Hoa BUI
Filed: 21 Sep 21
Utility
Compositions and Methods for Treating Late Stage Lung Cancer
10 Mar 22
Disclosed are methods for treating late stage (e.g., clinical stage III or IV), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD1/PD-L1 activity in a patient identified as having not progressed following definitive chemoradiation therapy.
Giovanni Melillo, Marc Ballas, Simon Dovedi, Ross Stewart
Filed: 18 Nov 21
Utility
Combination Treatment
10 Mar 22
The present invention relates to methods for treating ischemic events in a patient, especially ST-segment elevation myocardial infarction and acute ischemic stroke, by administrating a recombinant apyrase protein in conjunction with a P2Y12 inhibitor.
Leif CARLSSON, Sven NYLANDER, Ola FJELLSTROM, Lina BADIMON MAESTRO
Filed: 18 Aug 21
Utility
Pharmaceutical Process and Intermediates
24 Feb 22
Mark Andrew Graham, Lucinda Victoria Jackson, Gary Michael Noonan, Phillip Anthony INGLESBY, David Pranay DAVE, Katie Grace COOPER
Filed: 17 Dec 19
Utility
Gene modification assays
22 Feb 22
Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines.
Marcello Maresca, Amir Taheri-Ghahfarokhi, Mohammad Bohlooly-Yeganeh, Lorenz M. Mayr
Filed: 13 Jan 17
Utility
Improved Method for the Manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
17 Feb 22
Andrew Roy TURNER, Andrew Timothy TURNER, Gareth Paul HOWELL, Malcolm Allan Young GALL, Keith Raymond MULHOLLAND, Neil Keith ADLINGTON, Zhenping TIAN, Bo LIU, Qisun GONG, Wei YU
Filed: 10 Sep 19
Utility
Methods of Treating Homologous Recombination Deficient Cancer
17 Feb 22
This disclosure relates to methods of treating homologous recombination (HR) deficient cancers, such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer, and/or pancreatic cancer.
TSVETA PETROVA MILENKOVA-ILIEVA, ERIC PUJADE-LAURAINE, ISABELLE RAY-COQUARD
Filed: 11 Aug 21